Introduction: Finding newer modalities of treatment is the need of the hour for Colorectal carcinoma as the incidence of is on the rise. One such is the finding of overexpression of “Her-2/neu” a biological marker, with “Targeted therapy” which can open new avenues of treatment. Objectives: 1) To study the histopathology of neoplastic lesions in colonoscopic biopsies. 2) To determine the proportion of Her-2/neu overexpression in Colorectal Carcinomas. 3) To study association between Her-2/neu over expression with grade and lymph node status – wherever possible. Methods: All the histologically confirmed Colorectal Adenocarcinomas were subjected to Immunohistochemical staining for detection of Her-2/ neu overexpression. A “3+” complete membrane staining considered positive. Results: In the present study, Immunohistochemical staining of confirmed Adenocarcinomas with Her-2/neu for overexpression revealed a total of 16 (23.5%) cases as Positive, which were histologically low grade tumours, with a statistically significant p value of 0.0012. Conclusion: The incidence of colorectal carcinoma is on the rise at the rate of 2% annually. Herceptin , an antibody directed against Her-2/ neu antigen can be a novel therapy for the poor prognostic groups, which constituted around of 23.5% of cases in our study.

Keywords: Colonoscopy; Colorectal carcinoma; Her-2/neu; Immunohistochemistry.